未知生产厂商
PSN9301 is an oral small molecule inhibitor of Dipeptidyl Peptidase IV (DP-IV), being developed for the treatment of type 2 diabetes. PSN9301 has a very rapid onset and a relatively short duration of action, and available pre-clinical and clinical data indicate that it may be an ideal product candidate for meal-related dosing.
PSN9301 is an oral small molecule inhibitor of Dipeptidyl Peptidase IV (DP-IV), being developed for the treatment of type 2 diabetes. PSN9301 has a very rapid onset and a relatively short duration of action, and available pre-clinical and clinical data indicate that it may be an ideal product candidate for meal-related dosing.
PSN9301 is an oral small molecule inhibitor of Dipeptidyl Peptidase IV (DP-IV), an enzyme involved in the inactivation of the gut hormone glucagon-like peptide-1 (GLP-1). GLP-1 plays an important role in regulating meal-related blood glucose by increasing the amount of insulin secreted in response to meals. PSN9301 increases GLP-1 activity and causes significant lowering of blood glucose levels. The increase in insulin secretion in response to GLP-1 is glucose-dependent, providing a built in safety mechanism against low blood glucose levels (hypoglycaemia) in response to treatment with DP-IV inhibitors.
Investigated for use/treatment in diabetes mellitus type 1 and 2.
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
